If you've filled a prescription in the last few years, you've probably wondered why the same pill can cost $10 at one pharmacy and $150 at another — or why your insurance "covers" a drug but you still pay more than you would with a coupon. The answer, more often than not, traces back to a pharmacy benefit manager, or PBM.
In February 2026, Congress passed the most significant federal PBM legislation in the industry's history. This guide breaks down what PBMs actually do, why your prescriptions have been so expensive, what the new law changes, and — most importantly — when you might actually feel it in your wallet.
1. What Is a PBM? (The Travel Agent Analogy)
A pharmacy benefit manager is a company hired by your health plan to manage the prescription drug side of your benefits. Think of a PBM as a travel agent for prescriptions: it negotiates deals with airlines (drug manufacturers), decides which flights show up first when you search (the formulary — which drugs your plan covers and at what tier), and books your ticket at the counter (processes your claim at the pharmacy). Like a travel agent, a PBM can take a commission along the way — the problem is that, historically, patients had almost no visibility into how big that commission was or how it affected the final price.
PBMs handle three core jobs:
- Negotiating rebates with drug manufacturers in exchange for favorable formulary placement
- Building the formulary — deciding which drugs your plan covers, and at which copay tier
- Processing claims and reimbursing pharmacies when you pick up a prescription
Why this matters: The PBM market is extremely concentrated. Roughly 65 companies operate as PBMs today, but just three of them process approximately 80% of all prescription drug claims in the United States. That concentration is a major reason Congress and the FTC have focused so much scrutiny on the industry.
2. The Prescription Supply Chain, Step by Step
Here's the path your prescription actually takes before it reaches your hands — and where the money moves at each stop.
Manufacturer
Sets a list price, offers rebates to get favorable formulary placement
PBM
Negotiates rebates, builds the formulary, processes claims
Health plan / employer
Pays premiums and claims, ideally receives rebate savings
Pharmacy
Dispenses the drug, gets reimbursed by the PBM
You
Pay a copay or coinsurance, often based on list price
3. What Is Spread Pricing? (A Real Example)
One of the most criticized PBM practices is spread pricing — and it's easier to understand with numbers.
Example: Say your health plan pays its PBM $80 for a generic cholesterol medication. The PBM then reimburses the pharmacy that actually filled your prescription just $20 for that same drug. The PBM pockets the remaining $60 "spread" — without disclosing it to your employer or health plan. Multiplied across millions of claims, this hidden markup has been a major driver of rising drug spending that doesn't trace back to the manufacturer at all.
The new federal law aims to eliminate spread pricing in Medicare Part D entirely and requires detailed disclosure of spread pricing arrangements in commercial, employer-sponsored plans.
4. Why Do PBMs Favor Expensive Drugs?
This is the part that surprises most patients: for years, PBMs have often been paid based on a percentage of a drug's rebate or list price, rather than a flat fee for their services. That structure quietly rewards higher prices. A bigger rebate on a $500-a-month brand name drug is worth more to the PBM than a smaller rebate on a $50 generic — even when the cheaper drug works just as well clinically. Critics argue this incentive has helped keep list prices artificially high across the industry, since manufacturers can offer bigger rebates in exchange for better formulary placement.
5. What the 2026 Law Actually Changes
On February 3, 2026, President Trump signed the Consolidated Appropriations Act of 2026 (CAA 2026) into law, hours after the House passed it. It's the first comprehensive federal regulation of the PBM industry. The key provisions:
"Delinked" compensation for Medicare Part D
PBMs working with Medicare Part D plans can no longer earn income tied to a drug's price, rebates, discounts, or formulary placement. Instead, they can only receive a flat, "bona fide service fee" reflecting fair market value for work they actually performed.
100% rebate pass-through
PBMs must pass through all manufacturer rebates, fees, and other remuneration to the health plan or Part D sponsor — no more keeping a hidden cut. Rebate aggregators and group purchasing organizations must remit rebates to PBMs within 45 days of each quarter's end.
Mandatory transparency reporting
PBMs must submit detailed reports — at least twice a year for commercial plans, annually for Part D — covering drug-level spending, rebates, pharmacy reimbursement, spread pricing arrangements, and formulary placement rationale for high-cost drugs.
Enhanced audit rights and penalties
Health plans and Part D sponsors get expanded rights to audit their PBMs. Civil penalties for noncompliance can reach up to $10,000 per day for failing to disclose required information, and up to $100,000 per instance of knowingly false information.
A separate but related development: The Federal Trade Commission has also secured a settlement with one of the nation's largest PBMs over rebate practices the FTC alleged encouraged manufacturers to keep list prices high. The FTC estimates that settlement alone could reduce patient costs for drugs like insulin by as much as $7 billion over 10 years — though whether any individual patient benefits depends on choices their employer or insurer makes.
6. Timeline: When Will This Actually Affect You?
- February 3, 2026 CAA 2026 signed into law. No immediate change to your copay or coverage.
- Throughout 2026 Some PBMs move early and voluntarily. Cigna's Express Scripts and UnitedHealth's Optum Rx have both announced plans to eliminate rebate retention and pass rebates through to payers ahead of the mandatory deadline; CVS Caremark has offered pass-through options since 2019.
- 2026–2027 Federal agencies (the Department of Labor and CMS) issue implementing regulations and proposed rules that will shape exactly how the law is enforced.
- January 1, 2028 Medicare Part D and Medicare Advantage prescription drug plan provisions take effect — delinking, rebate pass-through, and reporting requirements become mandatory.
- January 1, 2029 Commercial, employer-sponsored (ERISA) plan provisions generally take effect for calendar-year plans — full rebate pass-through and disclosure requirements apply.
7. So, Will Your Drugs Actually Get Cheaper?
Honestly — it depends, and not right away. A few realistic caveats worth knowing:
- Effective dates are years out. Most enforceable requirements don't begin until 2028 or 2029, so don't expect your 2026 or 2027 copay to change because of this law alone.
- The law targets ERISA and Part D plans specifically. It doesn't directly regulate every PBM arrangement in every market segment, and Medicaid PBM practices are addressed through a separate GAO study rather than direct rule changes.
- Savings depend on what your employer does with the data. More transparency gives your health plan leverage to negotiate better PBM contracts — but it's up to your employer or insurer to act on that leverage and actually pass savings to you.
- Critics warn of workarounds. Some industry watchers caution that large PBMs could offset lost rebate revenue through higher administrative fees or other pricing mechanisms not directly addressed by the law.
8. PBM Glossary: Key Terms Explained
- Pharmacy Benefit Manager (PBM)
- A company that negotiates drug prices and rebates, builds drug formularies, and processes prescription claims on behalf of health plans.
- Rebate
- A payment a drug manufacturer gives to a PBM, often in exchange for favorable formulary placement — historically not always passed on in full to the health plan or patient.
- Spread pricing
- When a PBM charges a health plan more for a drug than it reimburses the pharmacy, keeping the difference as undisclosed profit.
- Delinking
- Separating PBM compensation from a drug's price, rebate amount, or formulary placement, so PBMs are paid flat fees instead of a cut of the transaction.
- Bona fide service fee (BFSF)
- A flat, fair-market-value fee for actual services a PBM performs — the only form of Part D compensation PBMs are now allowed to receive under the new law.
- Formulary
- The list of drugs a health plan covers, organized into cost tiers that determine your copay.
- Group purchasing organization (GPO) / rebate aggregator
- An entity that negotiates rebates on behalf of multiple PBMs or plans; now also subject to rebate remittance requirements under the new law.
9. What You Can Do Right Now
Ask your employer's HR or benefits team
Ask whether your health plan's PBM has already moved to a rebate pass-through model, and whether they've reviewed the plan's PBM contract in light of the new transparency rules.
Compare your copay against cash prices
Use a tool like a drug price checker, GoodRx, or Cost Plus Drugs to see whether paying cash is actually cheaper than your insurance copay for a given prescription today.
Read your plan's annual PBM notice
Under the new law, group health plans must send participants an annual written notice explaining that their PBM is required to file spending reports — don't skip past it when it arrives.
Report suspected overcharging
If you suspect deceptive pricing practices, you can file a complaint with your state insurance commissioner or the Federal Trade Commission.